Radiation for Lymphoma Involving the Brain and Spine — Whole-Brain, Focused, or Not at All

Radiation is used in three main situations. As consolidation after systemic treatment has cleared or shrunk the disease. As the main treatment when systemic therapy is not safe or has not worked. And urgently, to relieve pressure on the spinal cord or to treat an eye. It is rarely the first step.

That order matters, and it is the part most families are not told plainly. Lymphoma inside the brain and spinal cord behaves differently from a solid tumour sitting in one place. It is often scattered, and it responds to treatment that travels through the bloodstream and crosses into the brain. So systemic treatment leads. Radiation is added afterwards to deal with what remains, or held back entirely if the response was complete and the person is young.

Holding it back is a real option, not a refusal to treat. In younger patients with a good response, some teams defer radiation and keep it available for later, precisely because the cognitive cost of brain radiation lands over decades rather than weeks. In older patients, or where systemic treatment cannot be given safely, radiation moves up the list because it works and it works quickly.

It helps to separate two different things that both get called "side effects". In the first weeks, tiredness, a foggy head and hair loss over the treated area are common, and most of it settles. What guidance bodies mean by delayed neurotoxicity is different: a slow change in memory, concentration, word-finding, walking steadiness and sometimes bladder control that shows up much later and does not always improve on its own.

The size of that risk is not one number, and anyone who gives you one is over-simplifying. It depends on the total dose, whether the whole brain or a focused field was treated, what systemic treatment was given alongside it, and above all on age. ASTRO and NCCN guidance both describe the risk as substantially greater in people over sixty and after full-dose whole-brain treatment — which is exactly why the reduced-dose approach became standard practice for consolidation.

For a younger patient — the person this page is most often read for — the calculation is different again. The risk is lower per unit of dose, but the exposure window is five decades long instead of two. That is why a twenty-eight-year-old and a seventy-year-old with similar scans can reasonably be offered different plans, and why deferring radiation is discussed seriously in the younger case.

• Ask for baseline neurocognitive testing before treatment starts. A short formal assessment gives a reference point. Without it, later changes are argued about rather than measured.
• Ask what dose is proposed, and whether a lower one is reasonable. Reduced-dose consolidation exists for this reason. It is a legitimate question, not a challenge to your team.
• Ask whether memory structures can be spared in the plan. Whether it is possible depends on where the disease sits and what the centre can deliver — but it is worth asking.
• Ask whether radiation can be deferred. In younger patients with a complete response, keeping it in reserve is an accepted strategy at many centres.
• Ask who will follow the cognitive side afterwards. Repeat testing at set intervals, and a named person to raise concerns with, should be part of the plan from the start.
• Report changes early rather than adapting around them. Families usually notice slowed processing, repeated questions or unsteadiness before the patient does. Say so at the next review.

Late-effect risks vary widely with dose, field size, technique and age, and modern conformal planning spares far more healthy tissue than the wide fields used decades ago. Ask what your own plan involves rather than assuming an older estimate applies to you.

• New or worsening weakness in the legs — particularly with numbness that is creeping upwards. Where the spine is involved, this is treated as an emergency.
• Loss of bladder or bowel control — a red flag for cord compression. Function lost before treatment starts is the least likely to return, so hours matter.
• A seizure, or a first-ever blackout — needs assessment the same day, whether or not you have had one before.
• Severe headache with vomiting, or headache that is worse on waking — this pattern suggests rising pressure inside the skull and should not be managed at home.
• Sudden change in vision — blurring, loss of part of the visual field, or new floaters, especially where the eye is involved.
• New confusion, drowsiness or a change in personality — often noticed by family first. Report it rather than waiting to see whether it settles.

• If a transplant is part of the plan, radiation may be used as part of the conditioning before it — Radiation Before a Stem Cell Transplant explains where it fits and what it involves.
• For blood cancer deposits in bone rather than the nervous system, Radiation for Plasmacytoma and Myeloma Bone Lesions covers a different but neighbouring use of the same technique.
• Wondering why a field is drawn tightly around one site rather than a whole region? Involved-Site vs Involved-Field Radiation for Lymphoma explains the shift and why it lowers late effects.
• Once treatment ends, the surveillance runs for decades. Long-Term Follow-Up for Lymphoma Survivors Treated With Radiation sets out the schedule year by year.
• For the wider picture of how plans are built, delivered at NABH-accredited partner centres and coordinated by our team, see Radiation Therapy at CION Cancer Clinics.

Not sure whether the plan on the table is the right one? Book a free consultation and a radiation oncologist will go through it with you. Or call 1800 202 8726.